Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This facility manufactures APIs & formulations of oncology and non-oncology products.
A significant proportion of healthcare professionals still tend to favor branded drugs
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Fluid bed processes: drying, granulating, and coating in just one product container
Subscribe To Our Newsletter & Stay Updated